VIDA Diagnostics Inc., a medical software and services company based in the UI BioVentures Center and created through research at the UI College of Engineering, recently announced the company raised $5.1 million in Series B funding.
With an anticipated launch this summer of its signature invention—a device that allows patients with physical impairments to communicate with hospital staff—University of Iowa spinout company Voxello continues to draw significant investor interest while clinical trials are underway.
Sometimes, researchers need a helping hand to close the distance between a brilliant idea and a commercially viable product, service, or business.
That’s where the University of Iowa’s GAP Funding Program comes in.
Hillel Haim, University of Iowa assistant professor of microbiology, is working on establishing new approaches to inactivate human immunodeficiency virus type 1 (HIV-1) and to increase its sensitivity to antibodies elicited by vaccines.
Five-hundred meters underwater in the south Pacific, a marine sponge contains a compound with unique anti-cancer properties. The only problem is supply. The sponge is not quite easily accessible, and when it is found, it typically doesn’t yield enough material to study.
Brad Amendt, UI professor of anatomy and cell biology, is about to go commercial with his new class of microRNA inhibitors to be used in tissue reprogramming, tissue engineering, and bone formation. His team has developed a new plasmid based series of microRNA reagents.
The University of Iowa’s UI Ventures program has awarded $750,000 in GAP funding to 11 awardees for FY2015, helping faculty and other researchers bridge the cost of translating their work into commercial products, services, and businesses.